This effect of CAFs, the most abundant cellular component of tumor stroma, has been documented across a wide range of targeted therapy contexts, including inhibitors of EGFR and ALK in EGFR mutant and ALK+ NSCLC, respectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.